SCHEDULE 14A INORMATION

     Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act
                           of 1934  (Amendment No. ____)

Filed by the Registrant [ X ]
Filed by a Party other than the Registrant [    ]

Check the appropriate box:

[ ] Preliminary Proxy Statement
[ ] Confidential for Use of the Commission Only
     (as permitted by Rule 14a-6(e)(2))
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to ss.240.14a-11(c) or ss.240.14a-12


                            Techne Corporation
                (Name of Registrant as Specified In Its Charter)


     (Name of Person(s) Filing Proxy Statement, if other than the Registrant)


Payment of Filing Fee (Check the appropriate box):

[X]  No fee required

[ ]  Fee computed on table below per Exchange Act Rules  14a-6(i)(1)
     and 0-11

1)   Title of each class of securities to which transaction applies:

2)   Aggregate number of securities to which transaction applies:

3)   Per unit price or other underlying value of transaction computed
     pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
     filing fee is calculated and state how it was determined):

4)   Proposed maximum aggregate value of transaction:

5)   Total fee paid:

[ ]  Fee paid previously with preliminary materials.

[ ]  Check box if any part of the fee is offset as provided by Exchange
     Act Rule  0-11(a)(2) and identify the filing for which the offsetting
     fee was paid previously.  Identify the previous filing by registration
     statement number, or the Form or Schedule and the date of its filing:

1)   Amount Previously Paid:

2)   Form, Schedule or Registration Statement No.:

3)   Filing Party:

4)   Date Filed:


                        TECHNE CORPORATION


               NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
                            to be held
                         October 18, 2001


     The annual meeting of shareholders of Techne Corporation (the
"Company") will be held at the offices of the Company, 614 McKinley Place
N.E., Minneapolis, Minnesota, on Thursday, October 18, 2001, at 3:30 p.m.
(Central Daylight Time), for the following purposes:

     1. To set the number of members of the Board of Directors at eight (8).

     2. To elect directors of the Company for the ensuing year.

     3. To take action upon any other business that may properly come
        before the meeting or any adjournment thereof.

     Only shareholders of record shown on the books of the Company at the
close of business on September 11, 2001 will be entitled to vote at the
meeting or any adjournment thereof.  Each shareholder is entitled to one vote
per share on all matters to be voted on at the meeting.

     You are cordially invited to attend the meeting.  Whether or not you
plan to attend the meeting, please sign, date and return your Proxy in the
return envelope provided as soon as possible.  Your cooperation in promptly
signing and returning the Proxy will help avoid further solicitation expense
to the Company.

     This Notice, the Proxy Statement and the enclosed Proxy are sent to you
by order of the Board of Directors.




                                                THOMAS E. OLAND,
                                                President



Dated:  September 18, 2001
        Minneapolis, Minnesota




                           TECHNE CORPORATION

                               __________

                            PROXY STATEMENT
                                   for
                     Annual Meeting of Shareholders
                      to be held October 18, 2001
                               __________


                             INTRODUCTION

     Your Proxy is solicited by the Board of Directors of Techne Corporation
(the "Company") for use at the Annual Meeting of Shareholders to be held on
October 18, 2001 and at any adjournment thereof, for the purposes set forth
in the attached Notice of Annual Meeting.

     The cost of soliciting Proxies, including preparing, assembling and
mailing the Proxies and soliciting material, will be borne by the Company.
Directors, officers and regular employees of the Company may, without
compensation other than their regular compensation, solicit Proxies
personally or by telephone.

     Proxies not revoked will be voted in accordance with the choice
specified by shareholders by means of the ballot provided on the Proxy for
that purpose.  Proxies which are signed but which lack any such specification
will, subject to the following, be voted in favor of the proposals set forth
in the Notice of Meeting and in favor of the number and slate of directors
proposed by the Board of Directors and listed herein.  If a shareholder
abstains from voting as to any matter, then the shares held by such
shareholder shall be deemed present at the meeting for purposes of
determining a quorum and for purposes of calculating the vote with respect to
such matter, but shall not be deemed to have been voted in favor of such
matter.  Abstentions, therefore, as to any proposal will have the same effect
as votes against such proposal.  If a broker returns a "non-vote" proxy,
indicating a lack of voting instruction by the beneficial holder of the
shares and a lack of discretionary authority on the part of the broker to
vote on a particular matter, then the shares covered by such non-vote shall
be deemed present at the meeting for purposes of determining  a quorum but
shall not be deemed to be represented at the meeting for purposes of
calculating the vote required for approval of such matter.

     The mailing address of the Company's principal executive office is 614
McKinley Place N.E., Minneapolis, MN  55413.  The Company expects that this
Proxy Statement and the related Proxy and Notice of Annual Meeting will first
be mailed to shareholders on or about September 18, 2001.


                   OUTSTANDING SHARES AND VOTING RIGHTS

     The Board of Directors of the Company has fixed September 11, 2001 as
the record date for determining shareholders entitled to vote at the Annual
Meeting.  Persons who were not shareholders on such date will not be allowed
to vote at the Annual Meeting.  At the close of business on September 11,
2001, 41,443,688 shares of the  Company's Common Stock were issued and
outstanding.  Such Common Stock is the only outstanding class of stock of the
Company.  Each share of Common Stock is entitled to one vote on each matter
to be voted upon at the meeting.  Holders of the Common Stock are not
entitled to cumulative voting rights in the election of directors.


                         PRINCIPAL SHAREHOLDERS

     The following table provides information concerning the only persons
known to the Company to be the beneficial owners of more than five percent
(5%) of the Company's outstanding Common Stock as of September 11, 2001:

                                          Amount and
Name and Address                          Nature of Shares         Percent
of Beneficial Owner                       Beneficially Owned(1)    of Class(2)
--------------------------------------    ---------------------    ----------
Kopp Investment Advisors, Inc.                 3,760,597 (3)          9.1%
Kopp Holding Company and LeRoy C. Kopp
7701 France Avenue So.
Edina, MN 55435

Pilgrim, Baxter & Associates, Ltd.             3,222,000 (4)          7.8%
825 Duportial Road
Wayne, PA 19087

Thomas E. Oland                                1,741,498 (5)(6)       4.2%
614 McKinley Place N.E.
Minneapolis, MN  55413

______________

(1) Unless otherwise indicated, the person listed as the beneficial owner
    of the shares has sole voting and sole investment power over the
    shares.

(2) Shares not outstanding but deemed beneficially owned by virtue of the
    right of a person to acquire them as of September 11, 2001, or within
    sixty days of such date are treated as outstanding only when
    determining the percent owned by such individual and when determining
    the percent owned by the group.

(3) Sole voting power: 1,108,400 shares; sole investment power: 790,000;
    shared investment power: 2,970,597.

(4) Sole voting power: 3,204,600 shares; sole investment power: 3,222,000.

(5) Does not include 820,025 shares held by the Company's Stock Bonus Plan
    for accounts of employees other than Mr. Oland, which are included in
    the group total in the Management Shareholding table.  The Company's
    Board of Directors, acting by a majority vote, currently directs the
    Trustee as to the voting of such shares.  Including such 820,025
    shares, Mr. Oland, a Director of the Company, beneficially owns
    2,561,523 shares or 6.2% of total shares outstanding plus shares
    subject to options exercisable by him.

(6) Includes 976,920 shares owned directly, 90,098 held by the Company's
    Stock Bonus Plan for Mr. Oland's account, 68,556 shares held by Thomas
    Oland and Associates, 205,924 shares held by the Thomas Oland and
    Associates Profit Sharing Plan and Trust and 400,000 shares subject to
    stock options which are exercisable.


                            MANAGEMENT SHAREHOLDINGS

    The following table sets forth the number of shares of the Company's
Common Stock beneficially owned as of September 11, 2001, by each executive
officer of the Company named in the Summary Compensation Table, by each
director and by all directors and executive officers (including the named
individuals) as a group.  Shares beneficially owned by Mr. Oland constitute
4.2% of total shares outstanding plus shares subject to options exercisable
by him.  Each other individual beneficially owns less than one percent of
total shares outstanding plus shares subject to options exercisable by him or
her.  As a group, officers and directors beneficially own 9.4% of total
shares outstanding plus shares subject to options exercisable by them.

     Name of Director                           Number of Shares
     or Executive Officer Group                 Beneficially Owned(1)
     --------------------------                 --------------------
     Thomas E. Oland                            1,741,498 (2)(3)
     Roger C. Lucas, Ph.D.                         71,456 (4)(5)(6)
     Howard V. O'Connell                          242,200 (4)(6)(7)
     G. Arthur Herbert                            284,200 (4)(6)(8)
     Lowell E. Sears                              210,400 (4)(6)(9)
     James A. Weatherbee Ph.D.                    168,436 (10)
     Monica Tsang, Ph.D.                          179,862 (11)
     Christopher S. Henney, D.Sc, Ph.D.            20,000 (4)(6)(12)
     Randolph C. Steer, M.D., Ph.D.                70,000 (4)(6)(13)
     Marcel Veronneau                              54,899 (14)
     Timothy M. Heaney                             62,524 (15)
     Officers and directors as a group
       (11 persons)                             3,882,434 (16)

(1)  Unless otherwise indicated, the person listed as the beneficial owner
     has sole voting and sole investment power over outstanding shares.
     Shares beneficially owned includes shares subject to options which are
     currently outstanding and exercisable and options which are currently
     outstanding an will become exercisable within 60 days of September 11,
     2001.

(2)  See Note (5) to the preceding table.

(3)  See Note (6) to preceding table.

(4)  Does not include 910,123 shares held by the Company's Stock Bonus Plan,
     which are included in the total of officers and directors as a group.
     The Company's Board of Directors, acting by majority vote, currently
     directs the Trustee as to the voting of such shares.

(5)  Includes 10,000 shares owned by Dr. Lucas' wife and 30,000 shares
     subject to stock options.  Dr. Lucas disclaims beneficial ownership of
     the shares owned by his wife.

(6)  Does not include an option to purchase 5,000 shares which will be
     granted on and will become exercisable as of the date of the Annual
     Meeting pursuant to the 1998 Nonqualified Stock Option Plan.

(7)  Includes 27,700 shares owned by Mr. O'Connell's wife and 70,000 shares
     subject to options.  Mr. O'Connell disclaims beneficial ownership of
     the shares owned by his wife.

(8)  Includes 154,200 shares held by trusts and partnership of which Mr.
     Herbert is a trustee or partner and 130,000 shares subject to options.

(9)  Includes 400 shares held by a trust of which Mr. Sears is a trustee and
     210,000 shares subject to options.

(10) Includes 100,912 shares subject to stock options.  Does not include
     shares beneficially owned by Dr. Tsang, Dr. Weatherbee's wife.

(11) Includes 109,520 shares subject to stock options.  Does not include
     shares beneficially owned by Dr. Weatherbee, Dr. Tsang's husband.

(12) Includes 20,000 shares subject to options.

(13) Includes 70,000 shares subject to options.

(14) Includes 23,006 shares subject to options.

(15) Includes 420 shares owned by Mr. Heaney's wife, 1,400 shares owned by a
     family trust of which Mr. Heaney is a co-trustee, and 57,516 shares
     subject to options.  Mr. Heaney disclaims beneficial ownership of
     shares owned by his wife and the trust.  Does not include 909,935
     shares held by the Company's Stock Bonus Plan for accounts of employees
     other than Mr. Heaney.

(16) Includes 910,123 shares held by the Company's Stock Bonus Plan as to
     which the Company's Board of Directors directs the voting and 1,220,954
     shares which may be purchased pursuant to options.


                              ELECTION OF DIRECTORS
                              (Proposals #1 and #2)

General Information

     The Bylaws of the Company provide that the number of directors shall be
determined by the shareholders at each annual meeting.  The Board of
Directors recommends that the number of directors to be set at eight.  Under
applicable Minnesota law, approval of the proposal to set the number of
directors at eight, as well as the election of each nominee, requires the
affirmative vote of the holders of the greater of (1) a majority of the
voting power of the shares represented in person or by proxy at the Annual
Meeting with authority to vote on such matter or (2) a majority of the voting
power of the minimum number of shares that would constitute a quorum for the
transaction of business at the Annual Meeting.

     In the election of directors, each Proxy will be voted for each of the
nominees listed below unless the Proxy withholds a vote for one or more of
the nominees.  Each person elected as a director shall serve for a term of
one year or until his successor is duly elected and qualified.  All of the
nominees are members of the present Board of Directors.  If any of the
nominees should be unable to serve as a director by reason of death,
incapacity or other unexpected occurrence, the Proxies solicited by the Board
of Directors shall be voted by the proxy representatives for such substitute
nominee as is selected by the Board, or, in the absence of such selection,
for such fewer number of directors as results from such death, incapacity or
other unexpected occurrence.

     The following table provides certain information with respect to the
nominees for director.




                        Current
                        Position(s) with       Principle Occupation(s)  Director
Name               Age  Company                During Past Five Years    Since
-----------------  ---  ---------------------  -----------------------  --------
Thomas E. Oland     60  Chairman of the Board, Chairman of the Board,    1985
                        President, Treasurer   President and Treasurer
                        and Director           of the Company since
                                               December 1985 and
                                               President of Research
                                               and Diagnostic Systems,
                                               Inc. since July 1982

Roger C. Lucas,     58  Vice Chairman          Vice Chairman and         1985
Ph.D.                   and Director           Senior Scientific
                                               Advisor to the
                                               Company's Board since
                                               July 1995.  Chairman of
                                               Visual Circuits, a
                                               digital video company
                                               since August 1997, and
                                               director of
                                               ChemoCentryx, Inc., a
                                               partially-owned
                                               subsidiary of the
                                               Company.  Chief
                                               Scientific Officer,
                                               Executive Vice
                                               President and Secretary
                                               of the Company from
                                               December 1985 to March
                                               1995.  Director of
                                               Printware, Inc.


Howard V.          71  Director                Private investor since    1985
O'Connell                                      1990.  Chairman,
                                               President and Treasurer
                                               of John G. Kinnard and
                                               Company, Incorporated,
                                               a securities broker-
                                               dealer, from 1969 to
                                               1990.


G. Arthur         75  Director                 Principle of CEO          1989
 Herbert                                       Advisors, a management
                                               and financial
                                               consulting firm, since
                                               January 1989; from
                                               January 1969 to
                                               December 1988,
                                               President and Vice
                                               President  Manager of
                                               Electro-Science
                                               Management Corp., a
                                               manager of venture
                                               capital partnerships.

Randolph C.       51  Director                 Consultant to the         1990
Steer, M.D.,                                   pharmaceutical and
Ph.D.                                          biotechnology industries
                                               since 1989; Chairman
                                               (July 1999-August 2000)
                                               of Vicus.com, Inc.
                                               Director of BioCryst
                                               Pharmaceuticals, Inc.

Lowell E. Sears   50  Director                 Private investor since    1994
                                               April 1994. For more
                                               than five years prior
                                               thereto, Chief
                                               Financial Officer of
                                               Amgen Inc., a
                                               pharmaceutical company.
                                               Director of Neose
                                               Technologies, Inc.

Christopher S.    60  Director                 Chief Execuitve Officer   1996
Henney, D.Sc.,                                 of Dendreon Corp., a
Ph.D.                                          biotechnology company,
                                               since April 1995.
                                               Executive Vice
                                               President of ICOS
                                               Corporation, a
                                               biotechnology company,
                                               from April 1990 to
                                               April 1995.  Director
                                               of Dendreon Corp.,
                                               Sonus Pharmaceuticals
                                               and Bionomics Inc.

Timothy M.        55  Vice President           Vice President,           1999
Heaney                and Director             Secretary  and General
                                               Counsel of the Company
                                               since October 1999.
                                               From June 1972 to
                                               September 1999, an
                                               attorney with the firm
                                               of Fredrikson & Byron,
                                               P.A. and legal counsel
                                               to the Company since
                                               its inception.


Committee and Board Meetings

     The Company's Board of Directors has two standing Committees, the Audit
Committee and the Compensation Committee.  The Audit Committee (whose members
are Messrs. Herbert, O'Connell, Sears and Dr. Steer) is responsible for
reviewing the Company's internal audit procedures, the quarterly and annual
financial statements of the Company and, with the Company's independent
accountants, the results of the annual audit.  The Audit Committee also
establishes and oversees the implementation of the Company's cash investment
policy.  The Audit Committee met six times during fiscal 2001.  The
Compensation Committee (whose members are Drs. Henney and Steer and Messrs.
Herbert and O'Connell) recommends compensation for officers of the Company.
The Compensation Committee met three times during fiscal 2001.  In addition
to formal meetings, the Audit and Compensation Committees had numerous
telephone conferences regarding Committee business.  The Board does not have
a separate Nominating Committee, but functions as a whole in considering
nominations.

     During fiscal 2001, the Board held five meetings.  Each director
attended 75% or more of the total number of meetings of the Board and of
Committees of which he was a member.

Directors' Fees

     Directors who are not employees of the Company are compensated at the
rate of $25,000 per year for service on the Board and Committees of the
Board.  In addition, under the Company's 1998 Nonqualified Stock Option Plan,
outside directors automatically receive an option to purchase shares of the
Company's Common Stock on election and upon each re-election.  In connection
with the 2001 Annual Meeting of Shareholders, the number of shares subject to
the option granted to outside directors re-elected to the Board will be 5,000
per director.

Audit Committee Report

     The Audit Committee is composed of four independent directors and
operates under a written charter adopted by the Board of Directors (set forth
in Appendix A).  The Audit Committee assists the Board of Directors with
fulfilling its oversight responsibility regarding the quality and integrity
of the accounting, auditing and financial reporting practices of the Company.
In discharging its oversight responsibilities regarding the audit process,
the Audit Committee:

     (1) reviewed and discussed the audited financial statements with
         management;

     (2) discussed with the independent auditors the material required to
         be discussed by Statement on Auditing Standards No. 61; and

     (3) reviewed the written disclosures and the letter from the
         independent auditors required by the Independence Standards Board's
         Standard No.1, and discussed with the independent auditors any
         relationships that may impact their objectivity and independence.

     Based upon the review and discussions referred to above, the Audit
Committee recommended to the Board of Directors that the audited financial
statements be included in the Company's Annual Report on Form 10-K for the
fiscal year ended June 30, 2001 as filed with the Securities and Exchange
Commission.

                                           G. Arthur Herbert
                                           Howard V. O'Connell
                                           Lowell E. Sears
                                           Randolph C. Steer, M.D., Ph.D.
                                             Members of the Audit Committee




                              EXECUTIVE COMPENSATION

Compensation Committee Report on Executive Compensation

     Compensation Committee Interlocks and Insider Participation.  The
Compensation Committee of the Board of Directors of the Company is composed
of directors Christopher S. Henney, D.Sc., Ph.D., G. Arthur Herbert, Howard
V. O'Connell and Randolph C. Steer, M.D., Ph.D.  None of the members of the
Committee is or ever has been an employee or officer of the Company and none
is affiliated with any entity other than the Company with which an executive
officer of the Company is affiliated.

     Overview and Philosophy.  The Company's executive compensation program
is comprised of base salaries, annual performance bonuses comprised of a cash
and option component, long-term incentive compensation in the form of stock
options, and various benefits, including the Company's profit sharing and
savings plan and stock bonus plan in which all qualified employees of the
Company participate.  In addition, the Compensation Committee from time to
time may award special cash bonuses or stock options related to non-
recurring, extraordinary performance.

     The Compensation Committee has followed a policy of paying annual base
salaries which are on the moderate side of being competitive in its industry
and of awarding bonuses based on achievement of specific revenue, profit and
non-monetary goals.  If the goals are achieved, the officer receives an
option to purchase a number of shares with a fair market value on date of
grant equal to 20% of the officer's base salary and receives, at the election
of the officer, either a cash bonus equal to 20% of the officer's base salary
or an additional option to purchase a number of shares with a fair market
value on date of grant equal to 170% of the cash bonus alternative.  Bonuses
are awarded on a prorated basis if between 85% and 100% of the specific
revenue and profit goals are achieved.  The goals are established annually as
recommended by the Chief Executive Officer of the Company and approved by the
Compensation Committee.

     The Company has formal employment agreements with its full-time
executive officers, other than its President, effective through June 30,
2004, except Mr. Heaney's, whose agreement expires September 30, 2002.  See
"Employment Contracts and Change in Control Arrangements" below.  The
agreements provide for base salaries subject to annual review, bonuses as
described above, benefits as provided to all employees and severance
compensation dependent upon years of employment with or service to the
Company in the event that the officer's employment is terminated without
cause or in connection with a sale or merger of the Company.

     Compensation in 2001.  During fiscal 2001, the Company maintained its
principal compensation policies and made adjustments in base salaries to
reflect competitive industry and individual performance factors.  The
Committee, at the beginning of fiscal 2001, established performance criteria
for officers based 70% on growth in consolidated revenues and earnings and,
working through the Company's Chief Executive Officer, 30% on individual
goals which, if met, would permit each officer to earn a cash bonus and
additional stock options.  The Company achieved record revenues and earnings.
On the basis of performance against the criteria established, the Committee
at the close of fiscal 2001 awarded to Dr. Tsang, and Messrs. Veronneau and
Heaney the bonuses indicated in the table below under "Summary Compensation
Table" and, subsequent to fiscal year end, the options indicated in footnote
(2) to the table below under "Options/SAR Grants During 2001 Fiscal Year".
In further recognition of the officers' achievements, the Committee
established base salaries for fiscal 2002 as disclosed below under
"Employment Contracts and Change in Control Arrangements."

     General.  The Company provided medical and insurance benefits to its
executive officers, which are the same as those generally available to all
Company employees.  The Company has a profit sharing and savings plan in
which all qualified employees, including executive officers, participate.  In
fiscal 2001, 2000 and 1999, the Company has contributed to the plan an amount
equal to approximately 9%, 10% and 10% of gross wages, respectively.  One
half of the assets of the plan have been invested in Common Stock of the
Company.  The amount of perquisites allowed to executive officers, as
determined in accordance with rules of the Securities and Exchange
Commission, did not exceed 10% of salary in fiscal 2001.

     Chief Executive Officer Compensation.  Thomas E. Oland served as the
Company's Chief Executive Officer in fiscal 2001.  His compensation was
determined in accordance with the policies described above as applicable to
all executive officers.  His base salary was increased from $210,000 in
fiscal 2000 to $220,000 in fiscal 2001 in light of the Company's increase in
revenues and earnings.  For fiscal 2001 performance he earned but waived a
cash bonus.  In February of 1996 the Compensation Committee, in connection
with the Board's long-term strategic planning for the Company, adopted a
substantial long-term incentive for Mr. Oland in the form of options to
purchase an aggregate of 400,000 shares of the Common Stock of the Company at
$4.53 per share, the fair market value on the date of grant.  The options are
contingent on continued employment by the Company and have fully vested.  The
options will expire in February of 2006.

     Summary.  Aggregate executive compensation increased moderately in
fiscal 2001 and the Company awarded stock options to officers because the
Company achieved record revenues and earnings and individual officers
achieved performance goals.  The Compensation Committee intends to continue
its policy of paying relatively moderate base salaries, basing bonuses on
specific revenue, profit and performance goals and granting options to
provide long-term incentive.

                                         Christopher S. Henney, D.Sc., Ph.D.
                                         G. Arthur Herbert
                                         Howard V. O'Connell
                                         Randolph C. Steer, M.D., Ph.D.
                                           Members of the Compensation Committee


Employment Contracts and Change in Control Arrangements

     The Company has formal employment agreements with each of its full-time
executive officers with the exception of its President and Chief Executive
Officer, with whom the Company has an oral understanding. The agreements,
which in the cases of Dr. Tsang and Mr. Veronneau expire June 30, 2004 and in
the case of Mr. Heaney expires September 30, 2002, provide for base salaries
subject to annual review, bonuses as described in the Compensation Committee
Report contained in this Proxy Statement, benefits as provided to all
employees and severance compensation based upon years of employment by or
service to the Company in the event that the officer's employment is
terminated without cause or in connection with a sale or merger of the
Company.  Base salaries for fiscal 2002 for the executive officers named in
the Summary Compensation Table are as follows:  T. Oland - $225,000; M. Tsang
- $210,000; M. Veronneau - $130,000 and T. Heaney - $195,000.  Each of such
officers is also subject to a confidentiality and non-competition agreement,
which prohibits competition with the Company for a period of two years
following termination of employment with the Company.

Summary Compensation Table

     The following table sets forth certain information regarding
compensation paid during each of the Company's last three fiscal years to the
Company's President (who serves as Chief Executive Officer) and to the
Company's other executive officers whose salary and bonus for fiscal 2001
exceeded $100,000.  Not included in the table is Dr. James Weatherbee, Vice
President and Chief Scientific Officer, who was on medical leave and did not
receive any compensation from the Company in fiscal 2001.



                                                                        Long Term Compensation
                                                                        ----------------------
                                    Annual Compensation               Awards             Payouts
                               -----------------------------          ------             -------
                                                                          Securities
                                                              Restricted  Underlying  LTIP     All Other
Name and               Fiscal                                 Stock       Options     Payouts  Compen-
Principal Position      Year   Salary($)  Bonus($)  Other(1)  Awards($)   /SARs (#)    ($)     sation($)(2)
---------------------  ------  ---------  --------  --------  ----------  ----------  -------  ------------
                                                                       
Thomas E. Oland,        2001    220,000      0        None      None          0         None     18,459
Chairman of the Board   2000    210,000      0        None      None          0         None     20,141
and President           1999    199,500      0        None      None          0         None     19,258


Monica Tsang, Ph.D.,    2001    200,000    39,820     None      None          554       None     18,459
Vice President -        2000    180,000    36,000     None      None         2,600      None     20,141
Research                1999    164,000    33,000     None      None         3,148      None     19,258


Marcel Veronneau,       2001    122,000    24,290     None      None          338       None     15,612
Vice President -        2000    110,000    22,000     None      None         1,498      None     15,732
Hematology Operations   1999    101,000    19,000     None      None         1,994      None     14,410


Timothy M. Heaney,      2001    185,000    36,830     None      None          538       None     10,045
Vice President -        2000    117,123    35,000     None      None        100,000     None     None
Secretary and General
Counsel
________________



(1)  "None" indicates zero or an amount equal to less than 10% of the total
     amount of annual salary and bonus reported for the named executive officer.

(2)  For each individual the amount reflects Company contributions to Profit
     Sharing and Savings Plan (as to one-half) and Stock Bonus Plan (as to
     one-half), the latter in the form of shares of the Company's Common Stock.


Options/SAR Grants During 2001 Fiscal Year

     The following table provides information related to options granted to
the name executive officers during fiscal 2001.  The Company has not granted
any stock appreciation rights.



                                                                      Potential
                                                                      Realizable
                                                                   Value at Assumed
                                                                     Annual Rates
                                                                    of Stock Price
                                                                   Appreciation for
                          Individual Grants                           Option Term
                 -------------------------------------------       ----------------
                   Number of   Percent of
                  Securities    Total
                  Underlying  Options/SARs
                 Options/SARs  Granted to  Exercise or
                   Granted    Employees in Base Price  Expiration
Name                 (#)       Fiscal Year   ($/Sh)        Date   5% ($)  10% ($)
---------------- ------------ ------------ ----------- ---------- ------- -------
                                                        
Thomas E. Oland	      0            --           --           --     --      --
Monica Tsang,
  Ph.D.            554(1)(2)      0.10%      $65.00     6/30/07   $14,660 $34,163
Marcel Veronneau   338(1)(2)      0.06%      $65.00     6/30/07   $ 8,944 $20,843
Timothy M.
  Heaney           538(2)(3)      0.10%      $65.00     6/30/07   $14,236 $33,177



------------------
(1)  Such option is an incentive stock option and became exercisable July 1,
     2000.

(2)  Subsequent to fiscal 2001 year end, options for the indicated number of
     shares at an exercise price of $32.50 per share expiring June 30, 2008
     were granted:  M. Tsang - 1,226; M. Veronneau - 748; T. Heaney - 1,134.

(3)  Such option is a nonqualified stock option and became exercisable July
     1, 2000.



Option/SAR Exercises During 2001 Fiscal
Year and Fiscal Year End Options/SAR Values

     The following table provides information related to the only option
exercised by a name executive officer during the 2001 fiscal year and the
number and value of options held by each named executive officer at fiscal
year end.

                                                Number
                                             of Securities     Value of
                                              Underlying      Unexercised
                                             Unexercised     In-the-Money
                                             Options/SARs   Options/SARs at
                       Shares        Value   at FY-End (#)   FY-End ($)(2)
                     Acquired on   Realized  Exercisable/    Exercisable/
Name                 Exercise (#)   ($)(1)   Unexercisable   Unexercisable
-------------------  ------------  --------  -------------  ---------------
Thomas E. Oland	        2,688      $68,368     400,000/0     $11,187,480/0
Monica Tsang, Ph.D.       0        $     0     113,294/0      $3,234,703/0
Marcel Veronneau          0        $     0      22,258/0       $594,616/0
Timothy M. Heaney         0        $     0   45,270/41,668  $743,670/$692,731
______________________

(1)  Based on the difference between the closing price of the Company's Common
     Stock as reported by Nasdaq on the date of exercise and the option
     exercise price.

(2)  Based on the difference between the $32.50 per share closing price of the
     Company's Common Stock as reported by Nasdaq on June 30, 2001 and the
     options exercise price.


Stock Performance Chart

     The following chart compares the cumulative total shareholder return on
the Company's Common Stock with the S&P Midcap 400 Index and the S&P Midcap
Biotechnology Index.  The comparison assumes $100 was invested on June 30,
1996 in the Company's Common Stock and in each of the foregoing indices and
assumes reinvestment of dividends.

                                TOTAL SHAREHOLDER RETURN

						INDEXED RETURNS


Company/Index         June 1997  June 1998  June 1999  June 2000  June 2001
--------------------  ---------  ---------  ---------  ---------  ---------
TECHNE CORP             103.42     130.34     173.50     888.89     444.44
S&P MIDCAP 400 INDEX    123.33     156.82     183.74     214.94     234.01
BIOTECHNOLOGY-MID       101.38     105.52     202.94     430.55     458.56



                                INDEPENDENT AUDITORS

     Deloitte & Touche LLP acted as the Company's independent auditors for
the 2001 fiscal year and has been selected by the Board of Directors to
continue for the current fiscal year.  A representative of Deloitte & Touche
LLP is expected to be present at the shareholders' meeting, will have the
opportunity to make any desired comments, and will be available to respond to
appropriate questions.

Audit Fees

     The estimated aggregate fees billed and to be billed by Deloitte &
Touche LLP for professional services rendered in connection with the audit of
the Company's annual financial statements for fiscal 2001 and review of the
Company's Forms 10-Q for fiscal 2001 are $60,500.

Financial Information Systems Design and Implementation Fees

     Deloitte & Touche LLP did not provide to the Company any services
related to financial information systems design and implementation during
fiscal 2001.

All Other Fees

     The aggregate fees billed and to be billed by Deloitte & Touche LLP for
all other nonaudit services  rendered  to  the  Company  during  fiscal
2001, including fees for tax related services, employee benefit plan audits
and business consulting services  unrelated to financial information  systems
design and implementation are $71,300.  The Company's Audit Committee has
determined that provision of such non-audit services is compatible with
maintaining Deloitte & Touche LLP's independence and has determined there is
no conflict of interest.


          COMPLIANCE WITH SECTION 16(a) OF THE SECURITIES EXCHANGE ACT

     Section 16(a) of the Securities Exchange Act of 1934 requires the
Company's executive officers and directors, and persons who own more than 10
percent of the Company's Common Stock, to file with the Securities and
Exchange Commission initial reports of ownership and reports of changes in
ownership of Common Stock and other equity securities of the Company.
Officers, directors, and greater than 10 percent shareholders ("Insiders")
are required by SEC regulations to furnish the Company with copies of all
Section 16(a) forms they file.

     To the Company's knowledge, based on a review of the copies of such
reports furnished to the Company, during the fiscal year ended June 30, 2001,
all Section 16(a) filing requirements applicable to Insiders were met.


                         SHAREHOLDER PROPOSALS

     Any appropriate proposal submitted by a shareholder of the Company and
intended to be presented at the 2002 Annual Meeting must be received by the
Company at its offices by May 20, 2002 to be eligible for inclusion in the
Company's Proxy Statement and related Proxy for the 2002 Annual Meeting.

     Also, if a shareholder proposal intended to be presented at the 2002
Annual Meeting but not included in the Company's Proxy Statement and Proxy is
received by the Company after August 3, 2002, then management named in the
Company's Proxy for the 2002 Annual Meeting will have discretionary authority
to vote the shares represented by such proxies on the shareholder proposal,
if presented at the meeting, without including information about the proposal
in the Company's proxy materials.

                           OTHER BUSINESS

     The Board of Directors knows of no other matters to be presented at the
meeting.  If any other matter does properly come before the meeting, the
appointees named in the Proxies will vote the Proxies in accordance with
their best judgment.


                           ANNUAL REPORT

     A copy of the Company's Annual Report to Shareholders for the fiscal
year ended June 30, 2001, including financial statements, accompanies this
Notice of Annual Meeting and Proxy Statement.  No portion of the Annual
Report is incorporated herein or is to be considered proxy-soliciting
material.

     THE COMPANY WILL FURNISH WITHOUT CHARGE A COPY OF ITS ANNUAL REPORT ON
FORM 10-K FOR THE FISCAL YEAR ENDED JUNE 30, 2001, TO ANY SHAREHOLDER OF THE
COMPANY UPON WRITTEN REQUEST.  REQUESTS SHOULD BE SENT TO PRESIDENT, TECHNE
CORPORATION, 614 MCKINLEY PLACE N.E., MINNEAPOLIS, MINNESOTA 55413.


Dated:	September 18, 2001
	Minneapolis, Minnesota



                             APPENDIX A

                       AUDIT COMMITTEE CHARTER

The Audit Committee of the Company's Board of Directors shall be composed of
three or more directors who are "independent" as such term is defined in
applicable regulations of Nasdaq, and who are free of any relationship that,
in the opinion of the Board of Directors, would interfere with their exercise
of independent judgment as a committee member.  Each of the members of the
Audit Committee shall be a person who through prior experience is financially
sophisticated and familiar with financial oversight responsibilities.  The
independent auditors of the Company's financial statements shall be
accountable to the Audit Committee and to the Board of Directors of the
Company.

In carrying out these responsibilities, the Audit Committee will:

- Meet not fewer than four times per year.

- Review and recommend to the Board of Directors the independent auditors to
be selected to audit the financial statements of the Company and its
divisions and subsidiaries and, when appropriate, recommend the
replacement of the Company's auditors.

- Meet with the independent auditors and financial management of the Company
to review the scope of the proposed audit for the current year and the
audit procedures to be utilized, and at its conclusion to review such
audit, including any comments or recommendations of the independent
auditors.  Any changes in accounting principles shall be reviewed.

- Review with the independent auditors and the Company's financial and
accounting personnel the adequacy and effectiveness of the accounting and
financial controls of the Company, and elicit any recommendations for the
improvement of such internal control procedures or particular areas where
new or more detailed controls or procedures are desirable.  Particular
emphasis shall be given to the adequacy of such internal controls to
expose any payments, transactions, or procedures that might be deemed
illegal or otherwise improper.

- Provide sufficient opportunity for independent auditors to meet with the
members of the Audit Committee without members of management present.
Among the items to be discussed in these meetings are the independent
auditors' evaluation of the Company's financial, accounting, and auditing
personnel, and the cooperation that the independent auditors received
during the course of the audit.

- Oversee the independence of the independent auditors through appropriate
means including obtaining a written statement delineating all
relationships between the independent auditors and the Company and
determining whether and to what extent the objectivity and independence of
the auditors may be impacted by all relationships and services.

- Discuss with the independent auditors their qualitative judgments about
the appropriateness, not just the acceptability, of accounting principles
and financial disclosure practices used or proposed to be adopted by the
Company, particularly about the degree of aggressiveness or conservatism
of the Company's accounting principles and underlying estimates.

- Establish and review adherence to the Company's cash management and
investment policies.

- Provide the report for the Company's annual proxy statement required by
regulations of the Securities and Exchange Commission respecting
activities of the Committee and state whether the Committee recommends
inclusion of the Company's audited financial statements in the annual
report to be filed with Commission.

- Investigate any matter brought to its attention within the scope of its
duties, with the power to retain outside counsel or other consultants for
this purpose if, in its judgement, that is appropriate.

- Submit to the Board of Directors the minutes of all meetings of the Audit
Committee and discuss the material matters discussed at each committee
meeting with the Board of Directors.



                         TECHNE CORPORATION

             PROXY FOR ANNUAL MEETING OF SHAREHOLDERS


         THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS



The undersigned hereby appoints THOMAS E. OLAND and KATHLEEN BACKES, or
either of them acting alone, with full power of substitution, as proxies to
represent and vote, as designated below, all shares of Common Stock of Techne
Corporation registered in the name of the undersigned, at the Annual Meeting
of the Shareholders to be held on Thursday, October 18, 2001 at 3:30 p.m.
Central Daylight Time, at the offices of the Company, 614 McKinley Place
N.E., Minneapolis, Minnesota, and at all adjournments of such meeting.  The
undersigned hereby revokes all proxies previously granted with respect to
such meeting.

The Board of Directors recommends that you vote "FOR" the following
proposals:

(1) To set the number of Directors at eight:

    [    ] FOR           [    ] AGAINST         [    ] ABSTAIN

(2) To elect Directors:  Nominees:  Thomas E. Oland, Roger C. Lucas, Ph.D.,
    Howard V. O'Connell, G. Arthur Herbert, Randolph C. Steer, M.D., Ph.D.,
    Lowell E. Sears, Christopher S. Henney, D.Sc., Ph.D. and Timothy M.
    Heaney

    [    ] FOR all Nominees listed above   [    ] WITHOUT AUTHORITY
           (except those whose names have         to vote for all nominees
           been written on the line below)        listed above

    (To withhold authority to vote for any nominee, write that nominee's
    name on the line below.)

    ____________________________________________________________________

(3) Other matters:  In their discretion, the appointed proxies are
    authorized to vote upon such other business as may properly come before
    the Meeting or any adjournment.


THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED OR, IF NO
DIRECTION IS GIVEN FOR A PARTICULAR PROPOSAL, WILL BE VOTED FOR SUCH
PROPOSAL.

Date_________________________, 2001.


                                       ___________________________________


                                       ____________________________________
                                       PLEASE DATE AND SIGN ABOVE
                                       exactly as name appears at the left,
                                       indicating, where appropriate
                                       official  position or
                                       representative capacity.
                                       If stock is held in joint
                                       tenancy, each joint owner
                                       should sign.